These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review. Tan S; Chen P; Ji J; Guo S; Yu D; Asakawa T; Zhou Y; Abe M; Zong L Dis Markers; 2018; 2018():1368617. PubMed ID: 30224936 [TBL] [Abstract][Full Text] [Related]
46. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report. Wu C; Zhang J; Wu X Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435 [TBL] [Abstract][Full Text] [Related]
47. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160 [TBL] [Abstract][Full Text] [Related]
48. Ripretinib: First Approval. Dhillon S Drugs; 2020 Jul; 80(11):1133-1138. PubMed ID: 32578014 [TBL] [Abstract][Full Text] [Related]
49. Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review. Zhang Y; Huang Z Front Pharmacol; 2023; 14():1122885. PubMed ID: 37288114 [No Abstract] [Full Text] [Related]
50. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China. Li J; Zhang J; Zhang Y; Qiu H; Zhou Y; Zhou Y; Zhang X; Zhou Y; Zhu Y; Li Y; Wang M; Shen K; Tao K; Wu X; Wang H; Zhang B; Ling J; Ye Y; Wu X; Qu H; Ma Y; Jiao X; Zheng H; Jin J; Liu Z; Tan M; Fang Y; Zhang P; Zhang N; Lei C; Cai Z; Liang B; Peng Z; Huang Z; Dong J; Shen L Eur J Cancer; 2024 Jan; 196():113439. PubMed ID: 37980854 [TBL] [Abstract][Full Text] [Related]
51. Gastrointestinal stromal tumor: a review of current and emerging therapies. Al-Share B; Alloghbi A; Al Hallak MN; Uddin H; Azmi A; Mohammad RM; Kim SH; Shields AF; Philip PA Cancer Metastasis Rev; 2021 Jun; 40(2):625-641. PubMed ID: 33876372 [TBL] [Abstract][Full Text] [Related]
52. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875 [TBL] [Abstract][Full Text] [Related]
53. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. Corless CL; Schroeder A; Griffith D; Town A; McGreevey L; Harrell P; Shiraga S; Bainbridge T; Morich J; Heinrich MC J Clin Oncol; 2005 Aug; 23(23):5357-64. PubMed ID: 15928335 [TBL] [Abstract][Full Text] [Related]
54. Next questions for the medical treatment of gastrointestinal stromal tumor. Italiano A Curr Opin Oncol; 2022 Jul; 34(4):348-353. PubMed ID: 35730519 [TBL] [Abstract][Full Text] [Related]
55. Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. Teranishi R; Takahashi T; Obata Y; Nishida T; Ohkubo S; Kazuno H; Saito Y; Serada S; Fujimoto M; Kurokawa Y; Saito T; Yamamoto K; Yamashita K; Tanaka K; Makino T; Nakajima K; Hirota S; Naka T; Eguchi H; Doki Y Int J Cancer; 2023 Jun; 152(12):2580-2593. PubMed ID: 36752576 [TBL] [Abstract][Full Text] [Related]
56. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. Liegl B; Kepten I; Le C; Zhu M; Demetri GD; Heinrich MC; Fletcher CD; Corless CL; Fletcher JA J Pathol; 2008 Sep; 216(1):64-74. PubMed ID: 18623623 [TBL] [Abstract][Full Text] [Related]
57. Precision medicine in gastrointestinal stromal tumors. Florou V; Trent JC; Wilky BA Discov Med; 2019; 28(155):267-276. PubMed ID: 32053767 [TBL] [Abstract][Full Text] [Related]
58. Targeted therapy and personalized medicine in gastrointestinal stromal tumors: drug resistance, mechanisms, and treatment strategies. Li GZ; Raut CP Onco Targets Ther; 2019; 12():5123-5133. PubMed ID: 31308690 [TBL] [Abstract][Full Text] [Related]
59. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors. Serrano C; Bauer S Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196 [TBL] [Abstract][Full Text] [Related]